Estrone

Estrone

SCHEMBL3825602

C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CCC2=O.O=S(=O)(O)C(F)(F)F

nearest known ligand 0.81

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ESR1

The experimentally established mechanism targets of Estrone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 known ✓ P03372 2/20 0.81
STS P08842 10/20 0.81
HSD17B1 P14061 4/20 0.81
CYP19A1 P11511 3/20 0.81
LMNA P02545 2/20 0.81
MAPT P10636 2/20 0.81
CYP3A4 P08684 2/20 0.81
ESR2 Q92731 2/20 0.81
AKR1B10 O60218 1/20 0.81
SHBG P04278 1/20 0.81
CYP1A2 P05177 1/20 0.81
PGR P06401 1/20 0.81
SERPINA6 P08185 1/20 0.81
AR P10275 1/20 0.81
AKR1B1 P15121 1/20 0.81
NFKB1 P19838 1/20 0.81
SLC6A4 P31645 1/20 0.81
OPRM1 P35372 1/20 0.81
SNCA P37840 1/20 0.81
HTR2B P41595 1/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Estrone SCHEMBL22847 0.92 STS (0.91) STSHSD17B1CYP19A1LMNAMAPT
Estrone SCHEMBL6693553 0.92 STS (0.91) STSHSD17B1CYP19A1LMNAMAPT
Estrone SCHEMBL8901907 0.91 STS (0.89) STSHSD17B1CYP19A1LMNAMAPT
Estrone SCHEMBL669802 0.91 STS (0.89) STSHSD17B1CYP19A1LMNAMAPT
Estrone SCHEMBL22551313 0.91 STS (0.89) STSHSD17B1CYP19A1LMNAMAPT
Estrone SCHEMBL628643 0.90 STS (0.87) STSHSD17B1CYP19A1LMNAMAPT
Estrone SCHEMBL12054811 0.90 CYP19A1 (1.00) STSHSD17B1CYP19A1LMNAMAPT
Estrone SCHEMBL7831317 0.90 CYP19A1 (1.00) STSHSD17B1CYP19A1LMNAMAPT
Estrone SCHEMBL15079288 0.90 CYP19A1 (1.00) STSHSD17B1CYP19A1LMNAMAPT
Estrone SCHEMBL157262 0.90 CYP19A1 (1.00) STSHSD17B1CYP19A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117324042-A Catalytic system for deoxidizing phenolic derivative, and mild and efficient deoxidizing method and application thereof 中国科学院长春应用化学研究所 2024-01-02 CN disclosed
US-11072632-B2 Inhibitors of 17β-HSD1, 17β-HSD3 and 17β-HSD10 UNIVERSITé LAVAL (CA) 2021-07-27 US disclosed
EP-2688901-B1 INHIBITORS OF 17ß-HSD1, 17ß-HSD3 AND 17ß-HSD10 UNIV LAVAL (CA) 2019-05-08 EP disclosed
EP-2774923-B1 METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE UNIV NAGOYA NAT UNIV CORP (JP) 2016-05-18 EP disclosed
US-8993777-B2 Method for producing phenyl-substituted heterocyclic derivative NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) 2015-03-31 US disclosed
US-20140275549-A1 METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) 2014-09-18 US disclosed
EP-2774923-A1 METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE National University Corporation Nagoya University (JP) 2014-09-10 EP disclosed
US-8754251-B2 Cyclopropyl PIDA boronate RIGEL PHARMACEUTICALS, INC. (US) 2014-06-17 US disclosed
US-20140088053-A1 INHIBITORS OF 17Beta-HSD1, 17Beta-HSD3 AND 17Beta-HSD10 UNIVERSITé LAVAL (CA) 2014-03-27 US disclosed
EP-2688901-A1 INHIBITORS OF 17ß-HSD1, 17ß-HSD3 AND 17ß-HSD10 Université Laval (CA) 2014-01-29 EP disclosed
US-20130331585-A1 CYCLOPROPYL PIDA BORONATE MIDCAP FINANCIAL TRUST 2013-12-12 US disclosed
US-8288367-B2 Treatment or inhibition of a steroid hormone dependent disorder; reducing spermatogenesis or male virility; 17 beta -hydroxysteroid dehydrogenase (17 beta-HSD) inhibitors; compounds such as 3-(benzylamino)-15alpha-(4-morpholin-4-yl-4-oxobutyl)estra-1(10),2,4-trien-17-one SOLVAY PHARMACEUTICALS GMBH (DE) 2012-10-16 US disclosed
WO-2012129673-A1 INHIBITORS OF 17ß-HSD1, 17ß-HSD3 AND 17ß-HSD10 UNIVERSITE LAVAL (CA) 2012-10-04 WO disclosed
EP-2099814-A1 SUBSTITUTED ESTRATRIEN DERIVATIVES AS 17BETA HSD INHIBITORS Solvay Pharmaceuticals GmbH (DE) 2009-09-16 EP disclosed
US-20080255075-A1 SUBSTITUTED ESTRATRIENE DERIVATIVES AS 17BETA HSD INHIBITORS SOLVAY PHARMACEUTICALS GMBH (DE) 2008-10-16 US disclosed
WO-2008065100-A1 SUBSTITUTED ESTRATRIEN DERIVATIVES AS 17BETA HSD INHIBITORS SOLVAY PHARMACEUTICALS GMBH (DE) 2008-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255075-A1 SUBSTITUTED ESTRATRIENE DERIVATIVES AS 17BETA HSD INHIBITORS HSD17B11, HSD17B1, HSD17B2 ESR1 113/4885STS 33/4885HSD17B1 2/4885
US-20130331585-A1 CYCLOPROPYL PIDA BORONATE PPIA, CDA, BCL6B ESR1 188/4885STS 3165/4885HSD17B1 172/4885
US-20140275549-A1 METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE PAH, DDT, NISCH ESR1 1602/4885STS 555/4885HSD17B1 1223/4885
US-11072632-B2 Inhibitors of 17β-HSD1, 17β-HSD3 and 17β-HSD10 HSD17B11, HSD17B3, HSD17B1 ESR1 72/4885STS 25/4885HSD17B1 3/4885
US-20140088053-A1 INHIBITORS OF 17Beta-HSD1, 17Beta-HSD3 AND 17Beta-HSD10 HSD17B11, HSD17B1, HSD17B3 ESR1 164/4885STS 26/4885HSD17B1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.